Article

A Literature Review of Cost-Benefit Analyses for the Treatment of Alcohol Dependence

Social and Epidemiological Research Department, Centre for Addiction and Mental Health, 33 Russell St., Toronto, Ontario M5S 2S1, Canada
International Journal of Environmental Research and Public Health (Impact Factor: 1.99). 08/2011; 8(8):3351-64. DOI: 10.3390/ijerph8083351
Source: PubMed

ABSTRACT The purpose of this study was to conduct a literature review of cost-benefit studies on pharmacotherapy and psychotherapy treatments of alcohol dependence (AD). A literature search was performed in multiple electronic bibliographic databases. The search identified seven psychotherapy studies from the USA and two pharmacotherapy studies from Europe. In the psychotherapy studies, major benefits are typically seen within the first six months of treatment. The benefit-cost ratio ranged from 1.89 to 39.0. Treatment with acamprosate was found to accrue a net benefit of 21,301 BEF (528 €) per patient over a 24-month period in Belgium and lifetime benefit for each patient in Spain was estimated to be Pta. 3,914,680 (23,528 €). To date, only a few studies exist that have examined the cost-benefit of psychotherapy or pharmacotherapy treatment of AD. Most of the available treatment options for AD appear to produce marked economic benefits.

Full-text

Available from: Svetlana Popova, Jun 03, 2015
0 Followers
 · 
261 Views
  • [Show abstract] [Hide abstract]
    ABSTRACT: War-related medical costs for U.S. veterans of Iraq and Afghanistan may be enormous because of differences between these wars and previous conflicts: (1) Many veterans survive injuries that would have killed them in past wars, and (2) improvised explosive device attacks have caused "polytraumatic" injuries (multiple amputations; brain injury; severe facial trauma or blindness) that require decades of costly rehabilitation. In 2035, today's veterans will be middle-aged, with health issues like those seen in aging Vietnam veterans, complicated by comorbidities of posttraumatic stress disorder, traumatic brain injury, and polytrauma. This article cites emerging knowledge about best practices that have demonstrated cost-effectiveness in mitigating the medical costs of war. We propose that clinicians employ early interventions (trauma care, physical therapy, early post-traumatic stress disorder diagnosis) and preventive health programs (smoking cessation, alcohol-abuse counseling, weight control, stress reduction) to treat primary medical conditions now so that we can avoid treating costly secondary and tertiary complications in 2035. (We should help an amputee reduce his cholesterol and maintain his weight at age 30, rather than treating his heart disease or diabetes at age 50.) Appropriate early interventions for primary illness should preserve veterans' functional status, ensure quality clinical care, and reduce the potentially enormous cost burden of their future health care.
    Military medicine 11/2012; 177(11):1235-44. DOI:10.7205/MILMED-D-12-00031 · 0.77 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Individuals with alcohol and/or drug use disorders often fail to receive care, or evidence-based care, yet the literature shows health economic benefits. Comparative effectiveness research is emerging that examines approved approaches in terms of real, total healthcare cost/utilization. Comprehensive retrospective insurance claims analyses are few but tend to be nationally distributed and large. The emerging pattern is that, while treatment in general is cost effective, specific therapeutics can yield different health economic outcomes. Cost/utilization data consistently show greater savings with pharmacotherapies (despite their costs) versus psychosocial treatment alone. All FDA-approved addiction pharmacotherapies (oral naltrexone, extended-release naltrexone, acamprosate, disulfiram, buprenorphine, buprenorphine/naloxone, and methadone) are intended for use in conjunction with psychosocial management, not as stand-alone therapeutics; hence, pharmacotherapy costs must offer benefits in addition to abstinence alone or psychological therapy. Patient persistence is problematic, and (despite its cost) extended-release pharmacotherapy may be associated with lower or no greater total healthcare cost, mostly due to reduced hospitalization. The reviewed studies use rigorous case-mix adjustment to balance treatment cohorts but lack the randomization that clinical trials use to protect against confounding. Unlike trials, however, these studies can offer generalizability to diverse populations, providers, and payment models—and are of particular salience to payers.
    Annals of the New York Academy of Sciences 09/2014; 1327(1). DOI:10.1111/nyas.12538 · 4.31 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Ziel: Ziel der Studie ist eine Schätzung der Inanspruchnahme gesundheitlicher Versorgung durch Alkoholabhängige. Geschätzt werden die Anzahl Alkoholabhängiger in der Allgemeinbevölkerung, die Anzahl der Betroffenen mit einer entsprechenden Diagnose und die Anzahl derer, die das Suchhilfesystem in Anspruch nahmen. Methodik: Die Schätzungen beruhen auf aktuellen Daten zur Inanspruchnahme von Einrichtungen der Gesundheitsversorgung. Die Verfahren zur Hochrechnung werden ausführlich beschrieben. Ergebnisse: In Deutschland wird der Anteil Alkoholabhängiger in der Allgemeinbevölkerung (18 +) für das Jahr 2012 auf 2,8% oder 1,86 Mio. Personen geschätzt. Eine Abhängigkeitsdiagnose bei niedergelassenen Ärzten erhielten etwa 649 000 Personen (Datenjahr 2009). Damit war etwa jeder dritte Alkoholabhängige (35,0%) im Gesundheitssystem registriert. Etwa 297 000 Abhängige befanden sich im gleichen Jahr in Behandlung im Krankenhaus und/oder ambulanten/stationären Suchthilfeeinrichtungen. Insgesamt liegt die Betreuungsquote bei etwa 16%. Der Anteil Alkoholabhängiger in stationärer Rehabilitationsbehandlung beträgt 1,8%. Schlussfolgerungen: Die Schätzungen machen deutlich, dass zur Vermeidung von Morbidität und Mortalität im Zusammenhang mit Alkoholabhängigkeit erhebliche Anstrengungen notwendig sind. Als Möglichkeiten werden die Erhöhung der Erreichungsquote Alkoholabhängiger durch Frühintervention und Diversifizierung des Behandlungsangebots sowie ein Paradigmenwechsel in der Abstinenzorientierung diskutiert. Abstract Aims: The study aims at estimating health care utilization of alcohol dependents. Estimates will be provided for the number of people with dependence in the general population, the number of people that have received the diagnosis “dependence” by a general practitioner, and number of people treated in addiction care. Methods: Estimates are based on the most recent data on health care utilization. The estima­tion methods are described in detail. Results: In Germany, the prevalence of alcohol dependence in the general population aged 18 years and above is estimated at 2.8% or 1.86 million individuals in 2012. Approximately 649 000 individuals were diagnosed as „alcohol dependent“ by a general practitioner indicating that about one third of the people with dependence (35.0%) were registered in the health care system (2009 data). In the same year approximately 297 000 individuals with alcohol dependence (16%) were utilizing specialized addiction services (in- or outpatient treatment, general hospital). The rate of addicts in rehabilitation treatment was estimated at 1.8%. Conclusions: For reducing the burden of morbidity and mortality associated with alcohol dependence considerable improvements in health care utilization by addicts are required. Utiliza­tion may be increased by improving excess to early intervention, diversification of treatment offers and challenging the paradigm of abstinence-­oriented treatment.
    Suchttherapie 08/2014; DOI:10.1055/s-0034-1376999 · 0.28 Impact Factor